The Experts below are selected from a list of 9675 Experts worldwide ranked by ideXlab platform
Jacqueline M Miller - One of the best experts on this subject based on the ideXlab platform.
-
five year antibody persistence and booster response after 1 or 2 doses of meningococcal a c w and y Tetanus Toxoid conjugate vaccine in healthy children
Pediatric Infectious Disease Journal, 2016Co-Authors: Nicola P. Klein, Yaela Baine, Devayani Kolhe, Carmen Baccarini, Jacqueline M Miller, Van Der Wielen MAbstract:Background:We evaluated antibody persistence up to 5 years postvaccination with a quadrivalent meningococcal serogroups A, C, W and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT), and subsequent booster responses to MenACWY-TT in healthy US children.Methods:In the initial phase II, open, multicente
-
immunogenicity safety and antibody persistence of a booster dose of quadrivalent meningococcal acwy Tetanus Toxoid conjugate vaccine compared with monovalent meningococcal serogroup c vaccine administered four years after primary vaccination using the same vaccines
Pediatric Infectious Disease Journal, 2015Co-Authors: Timo Vesikari, Marie Van Der Wielen, Veronique Bianco, Aino Forsten, Jacqueline M MillerAbstract:Background:We evaluated safety, immunogenicity and antibody persistence of meningococcal serogroups A, C, W and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT) booster vaccination 4 years after priming of toddlers.Methods:This phase III, open-label, controlled study in Finland (NCT00955682) enrolled
-
five year antibody persistence and booster response to a single dose of meningococcal a c w and y Tetanus Toxoid conjugate vaccine in adolescents and young adults an open randomized trial
Pediatric Infectious Disease Journal, 2015Co-Authors: Roger Baxter, Yaela Baine, Devayani Kolhe, Carmen Baccarini, Jacqueline M Miller, Marie Van Der WielenAbstract:Background:We evaluated antibody persistence after 1 dose of meningococcal serogroups ACWY Tetanus Toxoid (MenACWY-TT) or diphtheria Toxoid (MenACWY-DT) conjugate vaccines and subsequent booster responses to MenACWY-TT.Methods:In the initial phase II, open, multicenter study (NCT00454909), 872 parti
-
one or two doses of quadrivalent meningococcal serogroups a c w 135 and y Tetanus Toxoid conjugate vaccine is immunogenic in 9 to 12 month old children
Pediatric Infectious Disease Journal, 2013Co-Authors: Nicola P. Klein, Yaela Baine, Veronique Bianco, Leonard R Friedland, Mark M Blatter, Pascal Lestrate, Aftab Naz, Jacqueline M MillerAbstract:Background:The incidence of invasive meningococcal disease is highest in infants. A quadrivalent meningococcal serogroups A, C, W-135 and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT) was evaluated in children 9–12 months of age.Methods:We randomized infants (1:1) to receive 1 dose of MenACWY-TT a
-
immunogenicity and safety of an investigational combined haemophilus influenzae type b neisseria meningitidis serogroups c and y Tetanus Toxoid conjugate vaccine
Pediatric Infectious Disease Journal, 2011Co-Authors: Terry Nolan, Jacqueline M Miller, Peter Richmond, Helen Marshall, Jodie Mcvernon, Karyn Alexander, Narcisa Mesaros, Emmanuel Aris, Jan Poolman, Dominique BoutriauAbstract:Background:Neisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries. A Haemophilus influenzae type b-meningococcal serogroups C and Y-Tetanus Toxoid conjugate vaccine (HibMenCY-TT) was evaluated.Methods:A total of 1104 infants (randomized 3:1:1) were
Marc E Weksler - One of the best experts on this subject based on the ideXlab platform.
-
lower antibody response to Tetanus Toxoid associated with higher auto anti idiotypic antibody in old compared with young humans
Clinical and Experimental Immunology, 2008Co-Authors: E E Arreaza, James J Gibbons, Gregory W Siskind, Marc E WekslerAbstract:The production of anti-Tetanus Toxoid (TT) antibody and anti-anti-TT (auto-anti-Id) antibody has been measured in three young and three old persons. Both antibodies were measured using ELISA. We found that: (i) the anti-TT response of old subjects was lower than that of young subjects, (ii) serum auto-anti-Id antibody concentration was higher in old compared with young humans before boosting with TT, and (iii) anti-TT antibodies from different humans shared Id cross-reactivity when tested with a rabbit anti-Id antibody. Thus, the serum anti-TT antibody response to boosting was inversely correlated with the serum level of auto-anti-Id. This conclusion is consistent with the view that the higher level of auto-anti-antibody in older subjects contributes to their impaired antibody response to TT.
-
lower antibody response to Tetanus Toxoid associated with higher auto anti idiotypic antibody in old compared with young humans
Clinical and Experimental Immunology, 2008Co-Authors: E E Arreaza, James J Gibbons, Gregory W Siskind, Marc E WekslerAbstract:SUMMARY The production of anti-Tetanus Toxoid (TT) antibody and anti-anti-TT (auto-anti-Id) antibody has been measured in three young and three old persons. Both antibodies were measured using ELISA. We found that: (i) the anti-TT response of old subjects was lower than that of young subjects, (ii) scrum auto-anti-Id antibody concentration was higher in old compared with young humans before boosting with TT, and (iii) anti-TT antibodies from different humans shared Id cross-reactivity when tested with a rabbit anti-Id antibody. Thus, the serum anti-TT antibody response to boosting was inversely correlated with the serum level of auto-anti-Id. This conclusion is consistent with the view that the higher level of auto-anti-antibody in older subjects contributes to their impaired antibody response to TT.
E E Arreaza - One of the best experts on this subject based on the ideXlab platform.
-
lower antibody response to Tetanus Toxoid associated with higher auto anti idiotypic antibody in old compared with young humans
Clinical and Experimental Immunology, 2008Co-Authors: E E Arreaza, James J Gibbons, Gregory W Siskind, Marc E WekslerAbstract:The production of anti-Tetanus Toxoid (TT) antibody and anti-anti-TT (auto-anti-Id) antibody has been measured in three young and three old persons. Both antibodies were measured using ELISA. We found that: (i) the anti-TT response of old subjects was lower than that of young subjects, (ii) serum auto-anti-Id antibody concentration was higher in old compared with young humans before boosting with TT, and (iii) anti-TT antibodies from different humans shared Id cross-reactivity when tested with a rabbit anti-Id antibody. Thus, the serum anti-TT antibody response to boosting was inversely correlated with the serum level of auto-anti-Id. This conclusion is consistent with the view that the higher level of auto-anti-antibody in older subjects contributes to their impaired antibody response to TT.
-
lower antibody response to Tetanus Toxoid associated with higher auto anti idiotypic antibody in old compared with young humans
Clinical and Experimental Immunology, 2008Co-Authors: E E Arreaza, James J Gibbons, Gregory W Siskind, Marc E WekslerAbstract:SUMMARY The production of anti-Tetanus Toxoid (TT) antibody and anti-anti-TT (auto-anti-Id) antibody has been measured in three young and three old persons. Both antibodies were measured using ELISA. We found that: (i) the anti-TT response of old subjects was lower than that of young subjects, (ii) scrum auto-anti-Id antibody concentration was higher in old compared with young humans before boosting with TT, and (iii) anti-TT antibodies from different humans shared Id cross-reactivity when tested with a rabbit anti-Id antibody. Thus, the serum anti-TT antibody response to boosting was inversely correlated with the serum level of auto-anti-Id. This conclusion is consistent with the view that the higher level of auto-anti-antibody in older subjects contributes to their impaired antibody response to TT.
Yaela Baine - One of the best experts on this subject based on the ideXlab platform.
-
immunogenicity and safety of a quadrivalent meningococcal acwy Tetanus Toxoid conjugate vaccine 6 years after menc priming as toddlers
Pediatric Infectious Disease Journal, 2019Co-Authors: Terry Nolan, Yaela Baine, Peter Richmond, Robert Booy, Helen Marshall, Michael Nissen, John B Ziegler, Magali TraskineAbstract:Background:We assessed immunogenicity, antibody persistence and safety of the meningococcal serogroups A, C, W and Y-Tetanus Toxoid (TT) conjugate vaccine (MenACWY-TT) in children primed as toddlers with MenC vaccine.Methods:This open, multicenter extension study enrolled children 84–95 months of ag
-
five year antibody persistence and booster response after 1 or 2 doses of meningococcal a c w and y Tetanus Toxoid conjugate vaccine in healthy children
Pediatric Infectious Disease Journal, 2016Co-Authors: Nicola P. Klein, Yaela Baine, Devayani Kolhe, Carmen Baccarini, Jacqueline M Miller, Van Der Wielen MAbstract:Background:We evaluated antibody persistence up to 5 years postvaccination with a quadrivalent meningococcal serogroups A, C, W and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT), and subsequent booster responses to MenACWY-TT in healthy US children.Methods:In the initial phase II, open, multicente
-
five year antibody persistence and booster response to a single dose of meningococcal a c w and y Tetanus Toxoid conjugate vaccine in adolescents and young adults an open randomized trial
Pediatric Infectious Disease Journal, 2015Co-Authors: Roger Baxter, Yaela Baine, Devayani Kolhe, Carmen Baccarini, Jacqueline M Miller, Marie Van Der WielenAbstract:Background:We evaluated antibody persistence after 1 dose of meningococcal serogroups ACWY Tetanus Toxoid (MenACWY-TT) or diphtheria Toxoid (MenACWY-DT) conjugate vaccines and subsequent booster responses to MenACWY-TT.Methods:In the initial phase II, open, multicenter study (NCT00454909), 872 parti
-
one or two doses of quadrivalent meningococcal serogroups a c w 135 and y Tetanus Toxoid conjugate vaccine is immunogenic in 9 to 12 month old children
Pediatric Infectious Disease Journal, 2013Co-Authors: Nicola P. Klein, Yaela Baine, Veronique Bianco, Leonard R Friedland, Mark M Blatter, Pascal Lestrate, Aftab Naz, Jacqueline M MillerAbstract:Background:The incidence of invasive meningococcal disease is highest in infants. A quadrivalent meningococcal serogroups A, C, W-135 and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT) was evaluated in children 9–12 months of age.Methods:We randomized infants (1:1) to receive 1 dose of MenACWY-TT a
-
immunogenicity and safety of an investigational quadrivalent meningococcal acwy Tetanus Toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age
Pediatric Infectious Disease Journal, 2011Co-Authors: Roger Baxter, Yaela Baine, Kathleen Ensor, Veronique Bianco, Leonard R Friedland, Jacqueline M MillerAbstract:Background:An investigational quadrivalent Neisseria meningitidis serogroups A, C, W-135, and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT) has been developed to expand available options for vaccination against invasive meningococcal disease.Methods:A total of 784 healthy adolescents and young adu
Nicola P. Klein - One of the best experts on this subject based on the ideXlab platform.
-
Safety of repeated doses of Tetanus Toxoid, reduced diphtheria Toxoid, and acellular pertussis vaccine in adults and adolescents
Pharmacoepidemiology and Drug Safety, 2018Co-Authors: Michael L. Jackson, Jennifer C. Nelson, James D. Nordin, Nicola P. Klein, Onchee Yu, Sara Y. Tartof, James G. Donahue, Stephanie A. Irving, Jason M. Glanz, Michael M. McneilAbstract:In light of waning immunity to pertussis following receipt of Tetanus Toxoid, reduced diphtheria Toxoid and acellular pertussis (Tdap) vaccine, maintaining protection may require repeated Tdap vaccination. We evaluated the safety of repeated doses of Tetanus-containing vaccine in 68 915 nonpregnant adolescents and adults in the Vaccine Safety Datalink population who had received an initial dose of Tdap. Compared with 7521 subjects who received a subsequent dose of Tetanus Toxoid, reduced diphtheria (Td) vaccine, the 61 394 subjects who received a subsequent dose of Tdap did not have significantly elevated risk of medical visits for seizure, cranial nerve disorders, limb swelling, pain in limb, cellulitis, paralytic syndromes, or encephalopathy/encephalitis/meningitis. These results suggest that repeated Tdap vaccination has acceptable safety relative to Tdap vaccination followed by Td vaccination.
-
five year antibody persistence and booster response after 1 or 2 doses of meningococcal a c w and y Tetanus Toxoid conjugate vaccine in healthy children
Pediatric Infectious Disease Journal, 2016Co-Authors: Nicola P. Klein, Yaela Baine, Devayani Kolhe, Carmen Baccarini, Jacqueline M Miller, Van Der Wielen MAbstract:Background:We evaluated antibody persistence up to 5 years postvaccination with a quadrivalent meningococcal serogroups A, C, W and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT), and subsequent booster responses to MenACWY-TT in healthy US children.Methods:In the initial phase II, open, multicente
-
Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy
Obstetrics and gynecology, 2015Co-Authors: Lakshmi Sukumaran, Simon J. Hambidge, Natalie L. Mccarthy, Elyse O. Kharbanda, Eric Weintraub, Gabriela Vazquez-benitez, Michael M. Mcneil, Nicola P. Klein, Allison L. NalewayAbstract:OBJECTIVE:To evaluate the safety of coadministering Tetanus Toxoid, reduced diphtheria Toxoid, and acellular pertussis (Tdap) and influenza vaccines during pregnancy by comparing adverse events after concomitant and sequential vaccination.METHODS:We conducted a retrospective cohort study of pregnant
-
one or two doses of quadrivalent meningococcal serogroups a c w 135 and y Tetanus Toxoid conjugate vaccine is immunogenic in 9 to 12 month old children
Pediatric Infectious Disease Journal, 2013Co-Authors: Nicola P. Klein, Yaela Baine, Veronique Bianco, Leonard R Friedland, Mark M Blatter, Pascal Lestrate, Aftab Naz, Jacqueline M MillerAbstract:Background:The incidence of invasive meningococcal disease is highest in infants. A quadrivalent meningococcal serogroups A, C, W-135 and Y Tetanus Toxoid conjugate vaccine (MenACWY-TT) was evaluated in children 9–12 months of age.Methods:We randomized infants (1:1) to receive 1 dose of MenACWY-TT a